Immatics  Developing immunotherapies against solid tumours

In July 2020, immatics completed its reverse merger with Arya Sciences Acquisition Corp, a special purpose acquisition company (SPAC), and commenced trading on Nasdaq.

Leveraging its proprietary XPRESIDENT® platform, immatics has identified numerous MHC-bound peptide antigens expressed on tumour cells (TUMAPs) and these TUMAPs now serve as targets for diverse anti-cancer approaches, including adoptive cellular therapy, soluble T-cell receptors-based therapy and monoclonal antibodies. While pursuing its own preclinical and clinical pipeline of cancer therapeutics, immatics has formed a joint venture with the world’s largest cancer research center (MD Anderson Cancer Center, Houston, Texas) for the development of cell-based therapies. In parallel, immatics has created significant strategic collaborations with Roche, Amgen, Genmab, Celgene, GSK and BMS.

Industry

Therapeutics

Case facts

Location

Germany

Status

Active

Involved Team

Privacy Preference Center